Biocartis Group NV announced that Biocartis and Genomic Health, Inc. have agreed to terminate their collaboration, which was focused on the development of the Oncotype DX Breast Recurrence Score® test on Biocartis' molecular diagnostics platform Idylla. As a result of COVID-19, the project had been suspended earlier during 2020, with the project plan and timing under evaluation. The decision to now terminate the collaboration was driven by the uncertain timing of a product market release because of the pandemic and a decision by Exact Sciences to shift priorities to other initiatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.33M | |
+73.46% | 12.41B | |
-15.61% | 8.23B | |
+3.88% | 6.46B | |
+14.69% | 5.5B | |
-5.53% | 5.33B | |
+42.58% | 5.1B | |
-32.61% | 2.54B | |
+10.80% | 1.99B | |
-0.74% | 1.99B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances